We discovered in 2002 that the tetramerization (tet) domain of the tumor suppressor p53 can be converted from its native conformation to an alternative conformation with the characteristics of amyloid fibrils. Further, we observed that a cancer-associated mutant form of this domain, with Arg 337 mutated to His, exhibits a significantly heightened propensity to form fibrils compared to the wild-type domain, p53 is a structurally modular protein, and folding of the tet domain is required for tumor suppression. Previously, we showed that the R337H mutation destabilizes the tet domain in a pH-dependent manner and developed a molecular explanation for the tissue specificity of cancer associated with this mutation (adrenal cortical carcinoma (ACC) in children). We feel that there is a link between fibril formation and mutant p53 tumor biology. Consistent with findings for other cancer-associated mutant forms of p53, p53 with the R337H mutation (p53-R337H) accumulates at high levels in the nuclei of ACC tumor cells. Based on our findings for the mutant tet domain, we hypothesize that these nuclear accumulations have fibrilar structure. Further, we suggest that (some) other mutant forms of p53 accumulate in fibrilar structures. We seek to test these hypotheses through structural studies of multi-domain forms of wild-type and mutant p53. A variety of biophysical, biochemical and cell biology methods will be applied to study p53 molecules in vitro, in tumor cells, and in cultured cells derived from tumors.
Our aims are: 1) To determine whether wild-type and mutant p53 convert from the native state to amyloid fibrils in vitro, and 2) To determine whether aggregated forms of wild-type and mutant p53 in tumor cells exist in a fibrilar state. P53 is a multifunctional protein that is regulated at many levels, including transcription, post-translational modification and cellular localization. To understand tumorigenesis associated with mutations to p53, we must understand how these different regulatory processes are affected by mutations. While high-resolution structures and extensive biophysical data are available for several domains, the structural and biophysical properties of full-length p53 remain largely a mystery. Demonstrating that mutant p53 molecules exist as fibrils would explain the high stability reported for p53 accumulations and their nuclear localization, would provide a molecular explanation for loss of function, and would offer insights into the development of novel p53-directed therapeutics. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA104568-01
Application #
6703870
Study Section
Physical Biochemistry Study Section (PB)
Program Officer
Knowlton, John R
Project Start
2004-03-01
Project End
2006-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
1
Fiscal Year
2004
Total Cost
$135,000
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Galea, Charles A; High, Anthony A; Obenauer, John C et al. (2009) Large-scale analysis of thermostable, mammalian proteins provides insights into the intrinsically disordered proteome. J Proteome Res 8:211-26
West, Alina Nico; Ribeiro, Raul C; Jenkins, Jesse et al. (2006) Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res 66:5056-62
Galea, Charles A; Pagala, Vishwajeeth R; Obenauer, John C et al. (2006) Proteomic studies of the intrinsically unstructured mammalian proteome. J Proteome Res 5:2839-48
Galea, Charles; Bowman, Prentice; Kriwacki, Richard W (2005) Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils. Protein Sci 14:2993-3003